30 March - 5 April 2019
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
Mavenclad (cladribine) approved in USA
Mavenclad (cladribine) has been approved by the FDA, the US drug regulator, for relapsing forms of MS, including relapsing remitting MS and “active” secondary progressive MS. In the UK, Mavenclad has been approved as an NHS treatment since 2017.
MS Trust link: Mavenclad
Gabapentin and pregabalin reclassified
From April 1, gabapentin and pregabalin have been reclassified as controlled drugs. This has resulted in changes to how they are prescribed, particularly for repeat prescriptions.
MS Trust link: Gabapentin and pregabalin - new rules for prescriptions
Move it for MS Nick's story
7 Oct 2021 - 00:00
Nick, was diagnosed with relapsing remitting multiple sclerosis at the start of the first lockdown. In this story we talk to him about how he coped with his diagnosis and how running helps him with his MS.
David's diary - Inclusion and diversity, where are we now?
6 Oct 2021 - 00:00
Just over a year ago we published a diary entry about Inclusivity and Diversity at the MS Trust. In this piece we take a look at what's changed since then and what we still need to do.
Flu season 2021
4 Oct 2021 - 00:00
This year is likely to involve a bigger flu vaccination programme in the UK, including for people with multiple sclerosis (MS), due to the circulation of Covid-19 at the same time. Here we discuss who's eligible for a flu jab on the NHS and how to get one.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.